Literature DB >> 3014416

Prognostic factors for metastasis following proton beam irradiation of uveal melanomas.

E S Gragoudas, J M Seddon, K M Egan, L Polivogianis, C C Hsieh, M Goitein, L Verhey, J Munzenrider, M Austin-Seymour, M Urie.   

Abstract

Prognostic indicators for the development of metastasis following proton beam irradiation of uveal melanomas were evaluated for 510 patients treated from 1975 to 1984. Thirty-three patients developed metastasis (6.5%) from 3 to 51 months following treatment. The primary site of metastasis was the liver in 28 cases (85%). Both demographic and clinical factors were considered. The three leading predictors of survival without metastasis after proton beam irradiation in order of importance were: (1) largest diameter of the tumor; (2) location of the anterior margin of the tumor; and (3) age at treatment. Worse prognosis was associated with largest tumor diameter greater than 15.0 mm, tumor involvement of the ciliary body and age at treatment older than 59 years.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3014416     DOI: 10.1016/s0161-6420(86)33699-6

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  11 in total

1.  Uveal melanoma cell growth is inhibited by aminoimidazole carboxamide ribonucleotide (AICAR) partially through activation of AMP-dependent kinase.

Authors:  Ahmad Al-Moujahed; Fotini Nicolaou; Katarzyna Brodowska; Thanos D Papakostas; Anna Marmalidou; Bruce R Ksander; Joan W Miller; Evangelos Gragoudas; Demetrios G Vavvas
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-04-29       Impact factor: 4.799

2.  Proton therapy for uveal melanomas and other eye lesions.

Authors:  J E Munzenrider
Journal:  Strahlenther Onkol       Date:  1999-06       Impact factor: 3.621

3.  Risk factors for growth and metastasis of small choroidal melanocytic lesions.

Authors:  C L Shields; J A Shields; H Kiratli; P De Potter; J R Cater
Journal:  Trans Am Ophthalmol Soc       Date:  1995

4.  Prognostic factors of liver metastases from uveal melanoma.

Authors:  Laurent Kodjikian; Jean-Daniel Grange; Stéphano Baldo; Stéphanie Baillif; Justus G Garweg; Michel Rivoire
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-10-20       Impact factor: 3.117

5.  Predictive factors for the development of rubeosis following proton beam radiotherapy for uveal melanoma.

Authors:  A J Foss; I Whelehan; J L Hungerford; D F Anderson; R D Errington; A Kacperek; M Restori; J Kongerud; M Sheen
Journal:  Br J Ophthalmol       Date:  1997-09       Impact factor: 4.638

6.  Clinical Implications of Real-time Integrative Sequencing in Management of Patients With Suspected Germline BAP1 Mutations.

Authors:  Shayan Sengupta; Angela C Weyand; Santhosh A Upadhyaya; Yi-Mi Wu; Dan R Robinson; Rajen J Mody
Journal:  J Pediatr Hematol Oncol       Date:  2019-05       Impact factor: 1.289

Review 7.  Is observation really appropriate for small choroidal melanomas.

Authors:  J J Augsburger
Journal:  Trans Am Ophthalmol Soc       Date:  1993

Review 8.  The effectiveness and safety of proton radiation therapy for indications of the eye : a systematic review.

Authors:  Geertruida E Bekkering; Anne W S Rutjes; Vasiliy V Vlassov; Daniel M Aebersold; Konrade von Bremen; Peter Jüni; Jos Kleijnen
Journal:  Strahlenther Onkol       Date:  2009-04-16       Impact factor: 3.621

9.  Long-term risk of local failure after proton therapy for choroidal/ciliary body melanoma.

Authors:  Evangelos S Gragoudas; Anne Marie Lane; John Munzenrider; Kathleen M Egan; Wenjun Li
Journal:  Trans Am Ophthalmol Soc       Date:  2002

10.  Atypical Presentation: Metastatic Uveal Melanoma in a Young Patient without Visual Complaints.

Authors:  Pedro Grachinski Buiar; Sérgio Jobim de Azevedo
Journal:  Front Oncol       Date:  2017-05-18       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.